论文部分内容阅读
目的本研究主要观察E838对小鼠移植性淋巴瘤的体内抑瘤效果及相关的生物学指标,探讨合用137Csγ射线是否具有抑瘤增效作用。方法取2~3mm3淋巴瘤瘤块接种于IRM-2小鼠腋部皮下,24h后将荷瘤小鼠随机分为对照组、单放组、E838低、中、高药物组及药物合用照射组、环磷酰胺组。药物组与药物合用照射组对应性腹腔注射相同剂量E838,每日1次,连续7天,环磷酰胺隔日1次×4。合用照射组于给药的第4天进行全身1Gy照射,每日1次,连续5天。观察各组小鼠骨髓有核细胞数和肿瘤抑制率。结果E838 3个剂量对小鼠移植性淋巴细胞瘤的抑瘤率分别为(44.14±15.96)%、(70.74±11.17)%和(50.00±18.09)%,与对照组比较差异有统计学意义(P<0.001),骨髓有核细胞数与对照组相比则明显提高。E838合用137Csγ射线能提高抑瘤效果,抑瘤率分别为(65.43±2.13)%、(77.13±6.38)%和(67.55±11.17)%,(P<0.001),对肿瘤的杀伤作用高于单放组和单药治疗组。结论E838对小鼠肿瘤细胞具有良好的抑制作用,E838合用γ射线具有协同抑瘤作用,在适当剂量范围内可以促进荷瘤小鼠放疗后骨髓损伤修复。
Objective This study was to observe the inhibitory effect of E838 on the transplanted lymphoma in vivo and related biological indicators in mice to explore whether 137Csγ-rays combined with anti-tumor synergy. Methods Tumors of 2 ~ 3 mm3 lymphoma were inoculated subcutaneously in the axilla of IRM-2 mice. After 24 hours, the tumor-bearing mice were randomly divided into control group, single radiotherapy group, low, medium and high drug groups of E838, , Cyclophosphamide group. Drug group and drug combination irradiation group corresponding intraperitoneal injection of the same dose of E838, once daily for 7 days, cyclophosphamide every other day × 4. The combined irradiation group on the fourth day of administration of systemic 1Gy irradiation, once daily for 5 consecutive days. The number of bone marrow nucleated cells and tumor inhibition rate in each group were observed. Results The inhibitory rates of three doses of E838 on mice with transplanted lymphoblastoma were (44.14 ± 15.96)%, (70.74 ± 11.17)% and (50.00 ± 18.09)%, respectively, which were significantly different from those of the control group P <0.001), the number of bone marrow nucleated cells was significantly increased compared with the control group. E838 combined with 137Csγ-rays can enhance the anti-tumor effect, the tumor inhibition rates were (65.43 ± 2.13)%, (77.13 ± 6.38)% and (67.55 ± 11.17)%, Put group and monotherapy group. Conclusion E838 has a good inhibitory effect on mouse tumor cells. E838 combined with γ-ray has a synergistic anti-tumor effect. It can promote the repair of bone marrow damage in tumor-bearing mice after radiotherapy in the appropriate dose range.